CPMV (Mosaic ImmunoEngineering) LT-Debt-to-Total-Asset: 148.40 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Mosaic ImmunoEngineering LT-Debt-to-Total-Asset?

Mosaic ImmunoEngineering CPMV +11.11% LT-Debt-to-Total-Asset is 148.40 as of Mar. 2026. The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Mosaic ImmunoEngineering's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 148.40.

Mosaic ImmunoEngineering's long-term debt to total assets ratio increased from Mar. 2025 (14.40) to Mar. 2026 (148.40). It may suggest that Mosaic ImmunoEngineering is progressively becoming more dependent on debt to grow their business.

Mosaic ImmunoEngineering  (OTCPK:CPMV) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Mosaic ImmunoEngineering LT-Debt-to-Total-Asset Related Terms

Mosaic ImmunoEngineering LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Mosaic ImmunoEngineering's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mosaic ImmunoEngineering LT-Debt-to-Total-Asset Chart

Mosaic ImmunoEngineering Annual Data
Trend May16 May17 May18 May19 May20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.73 4.71 7.32 9.81 73.30

Mosaic ImmunoEngineering Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.40 24.64 26.31 73.30 148.40

Mosaic ImmunoEngineering LT-Debt-to-Total-Asset Calculation

Mosaic ImmunoEngineering's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=1.466/0.02
=

Mosaic ImmunoEngineering's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=1.484/0.01
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 148.40 mean?
Mosaic ImmunoEngineering (CPMV) has a LT-Debt-to-Total-Asset of 148.40 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Mosaic ImmunoEngineering and its competitors.
Is Mosaic ImmunoEngineering's LT-Debt-to-Total-Asset too high?
Mosaic ImmunoEngineering's current LT-Debt-to-Total-Asset is 148.40.
How does Mosaic ImmunoEngineering's LT-Debt-to-Total-Asset compare to TCRT and JAGX?
Mosaic ImmunoEngineering's LT-Debt-to-Total-Asset of 148.40 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Mosaic ImmunoEngineering and its competitors. Mosaic ImmunoEngineering's current LT-Debt-to-Total-Asset is 148.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mosaic ImmunoEngineering stock overvalued right now?
Mosaic ImmunoEngineering (CPMV) has a current LT-Debt-to-Total-Asset of 148.40. The current LT-Debt-to-Total-Asset is 148.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Mosaic ImmunoEngineering (CPMV), the current LT-Debt-to-Total-Asset is 148.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mosaic ImmunoEngineering Business Description

Address 9114 Adams Avenue, Suite 202, Huntington Beach, CA, USA, 92646
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions. The company is pursuing new product candidates and platforms to build a product pipeline based on its deep understanding of immunotherapies.